How the unfolding of notable infringement claim could alter commercial approaches for players in wider CBD treatment field.
David Knight
Advertisement
Articles by David Knight
Advertisement
Latest Updated Articles
Commercializing Cannabis and Patent LitigationPublished: February 10th 2021 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Johnson and Johnson’s Darzalex Faspro for Adults with High-Risk Smoldering Multiple Myeloma
2
Pharmaceutical Executive Daily: Lilly and Novo Nordisk Bring GLP-1s to TrumpRX
3
FDA Continues to Expand National Priority Voucher Program
4
Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?
5
